Rush Enterprises, Inc. announced strong third quarter 2026 results with revenues of $2.113 billion and net income of $78 million, up from $1.881 billion and $66.7 million respectively in Q3 2025. The company declared a $0.14 per share dividend and completed a strategic joint venture with MCT Companies, expanding into refrigerated transportation. Growth was driven by increased new truck deliveries, aftermarket services, and leasing revenue. Despite some industry order slowdowns awaiting EPA regulations, Rush expects continued demand improvement and strong sales into early 2027.
Rush Enterprises, Inc. third quarter 2026 results provide context for readers. For those tracking Industrials, 84 of 135 US stocks rose and 51 fell on Pluang. Notable movers as of Oct 28, 2026 03:12 WIB include LUNR at USD 11.50 (+9.73%), AMSC at USD 27.66 (+8.90%), and RKLB at USD 58.41 (+8.53%).
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
